X
<

What to Expect from Biogen in 2017

PART:
1 2 3 4 5 6 7
Part 7
What to Expect from Biogen in 2017 PART 7 OF 7

What Analysts Recommend for Biogen in June 2017

Biogen revenue trends

In 2016, Biogen (BIIB) reported revenues of $11.4 billion, which reflected a ~6% year-over-year (or YoY) growth. Wall Street analysts have estimated that Biogen’s revenue will be around $11.4 billion in 2017. Globally, ~38% of all multiple sclerosis (or MS) patients are treated with Biogen products. The company’s MS franchise generated revenues of around $2.2 billion in 1Q17.

In 1Q17, Biogen reported revenues of around $2.8 billion, which is 3% growth on a YoY basis and a 2% decline on a quarter-over-quarter basis. Biogen’s revenue growth may boost the share prices of the Health Care Select Sector SPDR Fund (XLV). Biogen holds ~2% of XLV’s total portfolio holdings.

What Analysts Recommend for Biogen in June 2017

Interested in ABBV? Don't miss the next report.

Receive e-mail alerts for new research on ABBV

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

1Q17 expenses

In 1Q17, Biogen reported GAAP R&D expenses of around $423 million, which is 15% of total revenues. The company reported SP&A expenses of around $499 million, which is ~18% of total revenues.

The above graph represents analysts’ ratings for Biogen from June 2016 to June 2017.

Analyst recommendations

A total of 27 analysts are covering Biogen in June 2017. Seven analysts recommended a “strong buy,” while nine analysts recommended a “buy.” Eleven analysts recommended a “hold.” About 59% of the analysts recommended some form of “buy.”

Competitor ratings

A total of 21 analysts were covering AbbVie (ABBV) in June 2017. Three analysts suggested a “strong buy,” seven suggested a “buy,” 11 recommended a hold, and none recommended a “sell” or “strong sell.” Around 48% of the analysts analyzing AbbVie suggested some form of “buy.”

In June 2017, 27 analysts were analyzing Sanofi (SNY). Four analysts recommended a “strong buy” while seven analysts recommended a “buy.” Fourteen analysts recommended a “hold” while two analysts recommended a “sell.” None of the analysts analyzing Sanofi recommended a “strong sell.” Around 41% of analysts suggested some form of “buy.”

32 analysts were analyzing Novartis (NVS) in June 2017. Six analysts recommended a “strong buy,” eight recommended a “buy,” 16 recommended a “hold,” while two recommended a “sell” for Novartis. None of the analysts suggested a “strong sell.” Around 43% of analysts recommended some form of “buy.”

X

Please select a profession that best describes you: